Table 3. Anatomic Site of SPMN According to First HNSCC by HPV-Relatedness in 12 618 Patients, SEER 2000 to 2014.
| Site of SPMNa | Observed | SIR Rate (95% CI) |
|---|---|---|
| First potentially HPV-associated HNSCC | ||
| All solid tumors | 3742 | 1.98 (1.91-2.04) |
| Gum and other mouth | 157 | 21.56 (18.32-25.21) |
| Floor of mouth | 67 | 18.29 (14.17-23.22) |
| Other oral cavity and pharynx | 28 | 17.26 (11.47-24.95) |
| Tongue | 345 | 16.18 (14.52-17.99) |
| Oropharynx | 35 | 11.99 (8.35-16.68) |
| Hypopharynx | 50 | 11.16 (8.28-14.71) |
| Pharynx | 107 | 10.85 (8.89-13.11) |
| Nasopharynx | 22 | 8.92 (5.59-13.50) |
| Esophagus | 162 | 5.47 (4.66-6.38) |
| Tonsil | 71 | 5.11 (3.99-6.44) |
| Larynx | 92 | 3.94 (3.18-4.83) |
| Lung and bronchus | 1059 | 3.63 (3.41-3.85) |
| Thyroid | 81 | 2.95 (2.35-3.67) |
| First non–HPV-associated HNSCC | ||
| All solid tumors | 8876 | 2.28 (2.23-2.32) |
| Gum and other mouth | 485 | 32.58 (29.75-35.62) |
| Floor of mouth | 187 | 29.92 (25.78-34.53) |
| Other oral cavity and pharynx | 68 | 23.66 (18.37-29.99) |
| Hypopharynx | 151 | 18.12 (15.34-21.25) |
| Tongue | 574 | 16.91 (15.55-18.35) |
| Lip | 130 | 14.83 (12.39-17.61) |
| Oropharynx | 67 | 14.1 (10.92-17.90) |
| Pharynx | 242 | 14.02 (12.31-15.90) |
| Larynx | 311 | 7.02 (6.26-7.85) |
| Tonsil | 128 | 6.87 (5.73-8.17) |
| Esophagus | 365 | 6.26 (5.63-6.93) |
| Salivary gland | 56 | 4.53 (3.42-5.88) |
| Lung and bronchus | 2969 | 4.47 (4.31-4.63) |
| Thyroid | 137 | 3.02 (2.53-3.57) |
| Liver | 150 | 1.94 (1.65-2.28) |
| Stomach | 116 | 1.46 (1.21-1.76) |
| Colorectal cancer | 402 | 1.29 (1.17-1.43) |
| Urinary bladder | 368 | 1.28 (1.15-1.42) |
Abbreviations: HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; SEER, Surveillance, Epidemiology, and End Results; SIR, standardized incidence ratio; SPMN, second primary malignant neoplasm.
a
Second primary malignant neoplasms are those with at least 1 excess case per 10 000 person-year at risk.